<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00901745</url>
  </required_header>
  <id_info>
    <org_study_id>FS/09/019/26905 - 1b</org_study_id>
    <nct_id>NCT00901745</nct_id>
  </id_info>
  <brief_title>Interaction of Apelin and Angiotensin in the Human Forearm Circulation</brief_title>
  <official_title>Investigating the Interaction of Apelin and Angiotensin II Peripheral Resistance Vessels in Vivo in Man</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Edinburgh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Edinburgh</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The apelin-APJ system is a relatively new discovery. It has generated interest in part due to
      it's apparent ability to counteract the renin-angiotensin system, which is frequently
      overactive in many cardiovascular disease.

      Apelin has the ability to cause blood vessels to relax, increasing their diameter and hence
      blood flow down the blood vessel. The researchers wish to investigate the hypothesis that an
      infusion of apelin will reduce the effects of angiotensin II, which is know to reduce the
      diameter of blood vessels.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2009</start_date>
  <completion_date type="Actual">April 2010</completion_date>
  <primary_completion_date type="Actual">April 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in angiotensin II mediated vasoconstriction</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in relevant neurohumoral hormones in response to apelin infusion</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Heart Disease</condition>
  <condition>Vasodilation</condition>
  <arm_group>
    <arm_group_label>Infusion of apelin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Using forearm venous occlusion plethysmography apelin will be infused to cause reduction in forearm blood flow. Infusion of angiotensin II and noradrenaline will given and vasoconstriction will be assessed. Blood samples for the infused arm and contra-lateral arm will be taken at regular time points to assess local and systemic changes in relevant hormones.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sodium nitroprusside infusion</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Using forearm venous occlusion plethysmography sodium nitroprusside will be infused to cause reduction in forearm blood flow. Infusion of angiotensin II and noradrenaline will given and vasoconstriction will be assessed. Blood samples for the infused arm and contra-lateral arm will be taken at regular time points to assess local and systemic changes in relevant hormones.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Angiotensin II</intervention_name>
    <description>Infusion of up to 30picmol/ml angiotensin II will be infused and respondent vasoconstriction assessed.</description>
    <arm_group_label>Infusion of apelin</arm_group_label>
    <arm_group_label>Sodium nitroprusside infusion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Noradrenaline infusion</intervention_name>
    <description>Infusion of up to 480 picomol/ml of noradrenaline will be infused.</description>
    <arm_group_label>Infusion of apelin</arm_group_label>
    <arm_group_label>Sodium nitroprusside infusion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  &gt; 18 years old

          -  Healthy volunteers

        Exclusion Criteria:

          -  Lack of informed consent

          -  Age &lt; 18 years,

          -  Current involvement in other research studies,

          -  Systolic blood pressure &gt;190 mmHg or &lt;100 mmHg

          -  Malignant arrhythmias

          -  Renal or hepatic failure

          -  Haemodynamically significant aortic stenosis

          -  Severe or significant co morbidity

          -  Women of childbearing potential.

          -  Any regular medication

               -  Previous history of any cardiovascular disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gareth D Barnes, MBChB</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Edinburgh</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clincial Research Facility, Royal Infirmary of Edinburgh, 51 Little France Cresc</name>
      <address>
        <city>Edinburgh</city>
        <zip>EH16 4SA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 13, 2009</study_first_submitted>
  <study_first_submitted_qc>May 13, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 14, 2009</study_first_posted>
  <last_update_submitted>August 9, 2010</last_update_submitted>
  <last_update_submitted_qc>August 9, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 10, 2010</last_update_posted>
  <responsible_party>
    <name_title>Dr Gareth Barnes</name_title>
    <organization>University of Edinburgh</organization>
  </responsible_party>
  <keyword>Renin angiotensin system</keyword>
  <keyword>Apelin</keyword>
  <keyword>Vasodilatation</keyword>
  <keyword>Heart disease</keyword>
  <keyword>Vascular biology</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Angiotensin II</mesh_term>
    <mesh_term>Norepinephrine</mesh_term>
    <mesh_term>Angiotensinogen</mesh_term>
    <mesh_term>Nitroprusside</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

